

AMENDMENTS TO THE CLAIMS

- 1 - 39. (Canceled)
40. (Previously Presented) A composition, comprising milk derived from a transgenic mammal and a recombinant transgenic polypeptide having a concentration of at least 0.5 mg/ml wherein said polypeptide comprises a completely γ -carboxylated Gla domain and a first amino acid sequence, wherein said first sequence is identical to a human prothrombin amino acid sequence.
41. (Canceled)
42. (Previously Presented) The composition of Claim 40, wherein polypeptide comprises a post-translational modification selected from the group consisting of glycosylation and proteolytic processing.
43. (Canceled)
44. (Previously Presented) The composition of Claim 40, wherein said polypeptide further comprises a second amino acid sequence, wherein said second sequence is identical to a mammalian thrombin amino acid sequence.
45. (Canceled)
46. (Previously Presented) The composition of Claim 44, wherein said mammalian thrombin comprises human thrombin.
- 47-55. (Canceled)
56. (Previously Presented) The composition of Claim 42, wherein said proteolytic processing comprises enzymatic cleavage selected from the group consisting of Factor Xa, Factor Va, venom protease, thrombin, and combinations thereof.

- 57. (Previously Presented) The composition of Claim 42, wherein said proteolytic processing comprises chemical activation selected from the group consisting of sodium citrate, protamine sulfate, polylysine, and combinations thereof.
- 58. (Previously Presented) The composition of Claim 42, wherein said proteolytic processing comprises, in combination, Factor Xa, Factor Va, calcium, and phospholipids.
- 59-60. (Canceled)
- 61. (Previously Presented) The composition of Claim 40, wherein said first amino acid sequence is 100% identical to said human prothrombin amino acid sequence, wherein upon activation said prothrombin sequence is capable of being converted into thrombin.